Harnessing NK and innate T cells from healthy donors, Sandhill’s proprietary co-activation and expansion technology results in a cytotoxic cellular immunotherapy with powerful tumor-killing ability.
Leveraging the properties of innate immunity, BINATE provides the potential for multiple dosing, improved safety, immediate off-the-shelf availability and enables cost-effective treatment everywhere from outlying clinics to large medical centers.
Gene-modified BINATE introduces specific targeting and enhanced cytotoxicity, providing even greater tumor killing activity.
